{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:06:03Z","timestamp":1788570363417,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin A nephropathy (IgAN) is a common immune-mediated kidney disease. Its pathogenesis involves dysregulated B cell activation, excessive production of galactose-deficient immunoglobulin A1 (Gd-IgA1), and formation of IgA immune complex, which collectively drive glomerular injury. Telitacicept, a fusion protein that blocks B cell activation pathways, may counteract these mechanisms, but observational data and reliable biomarkers of therapeutic response remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the clinical efficacy and safety of telitacicept and to determine whether changes in circulating B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and Poly-IgA immune complex (Poly-IgA) reflect treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective cohort study, 38 adult patients with IgAN received telitacicept combined with low-dose glucocorticoids for up to 9 months. Clinical outcomes, renal function, and safety events were monitored longitudinally, and serum biomarkers were analyzed to assess associations with remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Telitacicept treatment resulted in a substantial and sustained reduction in proteinuria while maintaining stable renal function, with over half of patients achieving complete or partial remission at 3 months. All three biomarkers reduced with treatment, and Poly-IgA showed the strongest correlation with clinical remission and the best ability to distinguish remission from non-remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept is an effective and well tolerated drug in the treatment of IgAN, with immunomodulatory effects consistent with suppression of pathogenic B cell activity. The lower level of Poly-IgA during treatment is significantly associated with clinical remission.It may serve as a promising biomarker for monitoring treatment response in the future, supporting its potential use in guiding individualized therapy for patients with IgAN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1751549","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:03:12Z","timestamp":1780034592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Rao","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Second Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Second Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Second Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Second Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Second Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","article-title":"Les ddp\u00f4ts intercapillaires d'IgA-IgG [intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama","year":"2014","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.003","article-title":"Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01300121","article-title":"Poly-IgA complexes and disease severity in IgA nephropathy","volume":"16","author":"Zhang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V9112048","article-title":"Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins","volume":"9","author":"Kokubo","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00883-8","article-title":"IgA glycosylation and immune complex formation in IgAN","volume":"43","author":"Suzuki","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","article-title":"Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis","volume":"82","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac107.003","article-title":"FC051: Atacicept reduces serum ANTI-GD-IGA1 levels in IgAN patients","volume":"37","author":"Barratt","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.11.026","article-title":"Novel treatment paradigms: primary IgA nephropathy","volume":"9","author":"Selvaskandan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.361","article-title":"Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG","volume":"52","author":"Tomana","year":"1997","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02974-9","article-title":"The predictive value of Oxford MEST-C classification to immunosuppressive therapy of IgA nephropathy","volume":"54","author":"Rui","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf261","article-title":"Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety","volume":"18","author":"He","year":"2025","journal-title":"Clin Kidney J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:03:12Z","timestamp":1780034592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1751549"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1751549","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1751549"}}